Studies on Changes in Some Indices of Liver Function in HIV/AIDS Patients in Highly Active Anti-Retroviral Therapy (HAART) in Imo State, Nigeria
Main Article Content
Abstract
A study on changes in some indices of liver function amongst HIV/AIDS patients on highly active anti-retroviral therapy (HAART) was conducted in Imo State between February 2022 and August 2023. A total of 722 Venous blood samples, comprising 24 serum 1 from HIV seropositive patients receiving highly active anti-retroviral therapy (HAART), 241 samples from HIV seropositive patients that have not commenced HAART and 240 samples from the control group. The blood samples were collected using sterile needles and syringes and were analyzed using standard biochemical methods for serum bilirubin, aspartate aminotransaminase, alanine aminotransaminase, alkaline phosphatase, serum protein and lipid profile. HIV/AIDS Seropositive patients on HAART showed a significant increase (P<0.25) in the mean aspartate aminotransaminase, alanine aminotransaminase, and alkaline phosphatase (10.32 ± 2.74, 8.71 ± 0.85, and 33.91 ± 0.37 in/L) and the control group (11.43 ± 2.73, 8.58 ± 0.49 and 34.17 ± 0.39 in/L). However, HIV/AIDS seropositive patients receiving HAART with hepatitis B virus co-infection showed a more significant increase (P<0.05) in the mean total and conjugated bilirubin, alanine aminotransaminase, aspartate aminotransaminase (48.2 ± 0.79, 30.90 ± 0.79, 37.72 ± 3.58, 49.70 ± 3.58 and 186.14 ± 13.15 in/L). No significant difference (P>0.05 was observed in the mean total cholesterol, triacylglycerol, HDL-Cholesterol, LDL-Cholesterol, Serum protein and bilirubin among HIV seropositive patients receiving HAART, when compared with the control group. The study has revealed that HIV/AIDS Patients on HAART are more likely to be predisposed to hepatic toxicity due to long-term dependency on HAART. Therefore, early diagnosis of hepatic dysfunction could promote safe and effective use of highly active anti-retroviral therapy among these patients.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Barbora, J.I Bunda C.P Kelta J.O (2020): Human Immunodeficiency Virus in Sub-Sahara African. Journal of Tropical Medicine and Hygiene, 32:91-97.
Barnett J.O Andy B.C Paul V.O( 2021): Clinical Effects of Antiretroviral Therapy in HIV infected Patients. International Journal of Infectious Diseases. 17:213-216.
Becher L.U 92020): Toxicity of Antiretroviral Drugs in the Liver. New England Journal of Medicine, 41:1614-1619.
Bonora, K.V. (2004). Inhibition of HIV-Progression with highly active antiretroviral therapy. American Journal of Infectious diseases 79:116-119.
Buski, J.V, Jugal B.Y. (2019). Impact of treating Human Immunodeficiency Virus with Protease Inhibitors. New England Journal of Medicine 340:1764-1769.
Carr, A.C Copper, D.A. (2020). Restoration of Immunity to Chronic Hepatitis B Infection in HIV_infected Patients on Protease inhibitor. Lancets, 348,995-996. DOI: https://doi.org/10.1016/S0140-6736(05)62892-9
Chirac, P.J volt, O.C. Pat, V.V (2018). Hepatotoxicity associated with Antiretroviral drugs. International Journal of Infectious Diseases 27:255-261.
Frieldwald, W.T., Levy, R.I Freeerickson, D.S. (1972). Estimation of concentration of Total Cholesterol in Plasma without the use of the Preparative ultracentrifuge. Clinical Chemistry 18:449-502. DOI: https://doi.org/10.1093/clinchem/18.6.499
King-Armstrong, V.M., (1964). Determination of serum Alkaline Phosphatase with Simplified Method. Clinical Chemistry 27:215-219.
Lambert, B.C. (2019). Spectrum of Hepatotoxicity in Human Immunodeficiency virus Patients on Highly Active antiretroviral therapy, European Journal of infectious Diseases, 94:41-47.
Lewis, G.X.D. (2021). Toxic Effect of Antiretroviral Drugs on Liver of HIV infected patients. Journal of Infectious Diseases 64:31-36.
Loffter, I.G.O. (2017). Antiretroviral Drug Induced Hepatotoxicity. The Role of Hepatitis C and B Virus on Immunodeficiency Virus. European journal of Tropical Medicine and Hygiene, 117:28-33.
Lopez, M.F., Stone, P., Ellis, S.E., Collwell, J.A., (1977). Cholesterol Determination in High Density Lipoprotein separated by three Different Methods: Clinical Chemistry 23:882-884. DOI: https://doi.org/10.1093/clinchem/23.5.882
Maat, V.H Bauser, M.B.C., Volter, G.B (2019). The consequences of Receiving Highly Active Antiretroviral Therapy, while living with HIV/AIDS. Journal of Acquired Immunodeficiency Syndrome, 22: 1431-1437.
Mallon, V.G. (2005). Low frequency of severe Hepatotoxicity and associated with HBsAg co-infection in HIV-positive patients treated with HAART. International journal of Acquired Immunodeficiency syndrome, 28: 114-121.
Malloy, J.M., and Evelyn C.B. (1937). Simple Manuel Method for Determination of serum bilirubin. Clinical chemistry 36:242-246.
Manfredi, R.U and Hopkins, V.C. (2022). Antiretroviral therapy and Hepatic Function; Emerging epidemiological, Pathogenic and clinical Issues and their consequences on diseases management. International Journal of Acquired Immunodeficiency syndrome, 17; 225-231.
Mark, S.T and Donald, B.O. (2021). Protease Inhibitors and Drugs Induced Liver Damage, American Journal of infectious Disease 35:90-97.
Marks, S.T and Bell K.J. (2021). Hepatotoxicity due to Non-Nucleoside Reserve Transcriptase Inhibitor in Inhibiting HIV Reverse Transcriptase. Lancet: 73:31-37.
Martinez, E.B., Blanco, J.L., Arnaiz, J.A. (2023). Hepatotoxicity in HIV-infected patients receiving Nevirapine containing antiretroviral therapy. Journal of Acquired Immunodeficiency syndrome, 15: 1261-12268. DOI: https://doi.org/10.1097/00002030-200107060-00007
Mendez, P.I Franklin, J.C., Sahegam, B.H (1975). Simple Manual Method for Determination of Serum Triacylglycerol. Clinical Chemistry 21:760-770. DOI: https://doi.org/10.1093/clinchem/21.6.768
Mohammed, G.I., Isah, J.O., Abdul, B.M. (2021). Incidence of severe liver damage in HIV patients Receiving Highly Active Antiretroviral Therapy. Journal of Biochemistry and Molecular Biology, 8:134-139.
Morgan, K.C. Bariltee, Y.M., Cole, V.B. (2020). Human Immunodeficiency Virus; A Global Menace, Mangement Strategies and Prevention. Journal of Applied Basic Science, 4:11-16.
Nigerian Bulletin on Epidemiology (1992). Origin and Prevalence of HIV/AIDS in Nigeria. Annual Epidemiology Record. 22:32-34.
Olufemi, O.B., Burmi, V.C Chitu, K.M. (2023). Immunodeficiency virus with Highly Active Antiretroviral Therapy. A Case Study of Western Nigeria. Journal of Travel Medicine, 4 2:11-14.
Pezzotti, P.R., Bougrini, R.C., Aceti, V.M. (2020). Hepatitis B and C Virus Infection; A Risk Factor for Severe Hepatic Cytolysis after Initiation of a protease inhibitor-containing Antiretroviral Regime in HIV-Infected Patients. Hepatology, 59: 15-19.
Poutt, C.N., Mac-Jones, I.B., Bray, S.K (2023). Hepatic Safety with Nevriapine and two Nucleosides in patients with Advanced HIV infection, from a Place-controlled Clinical end point Trails. Annals of Internal Medicine, 115: 12-219.
Reitman, J.K. and Frankel, F.C., (1957). Method for Determination of serum Amino transaminase. Clinical chemistry 49; 138-142.
Rutschman I.B.K., Puss-vay, D.C., Kelly, V.M. (2022). Efficacy and safety of combination Therapy with Infection-Alpha 2b and Ribavirin for severe chronic Hepatitis B and C Virus in HIV-infected patients. Journal of Acquired Immunodeficiency syndrome. 1:815-821.
Sandkamp, J.B. (1990). Determination of serum low-Density Lipoprotein. Clinical chemistry 36:219-221. DOI: https://doi.org/10.1093/clinchem/36.1.20
Spinetti, J.B and Donald’s (2020). Changes in Transaminases in Hepatitis B, C Virus and HIV-co infected patients on highly active antiretroviral therapy. Journal Tropical Medicine and Hygiene, 107:61-68.
World Health Organization (2020) Current and future Dimensions of the AIDS pandemic: a Capsule Summary. WHO/GRA/RES/SEI/92; 70-75.
Article Sidebar
